<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the third most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>Approximately 90% of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> <z:hpo ids='HP_0011420'>deaths</z:hpo> arise from the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Aberrant expression of Wnt5a, one of the WNT signaling factors, has been reported during <z:hpo ids='HP_0003003'>colon cancer</z:hpo> development and progression </plain></SENT>
<SENT sid="3" pm="."><plain>We found that both <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression of Wnt5a were decreased in the highly metastatic human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell line SW620 compared with the non-metastatic human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell SW480 </plain></SENT>
<SENT sid="4" pm="."><plain>This study tested the hypothesis that the silencing of Wnt5a in metastatic human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells is related to altered epigenetic modifications </plain></SENT>
<SENT sid="5" pm="."><plain>Wnt5a expression was not responsive to DNA methyltransferase inhibitor 5-aza-<z:chebi fb="0" ids="17562">cytidine</z:chebi> treatment </plain></SENT>
<SENT sid="6" pm="."><plain>However, <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase (HDAC) inhibitors <z:chebi fb="0" ids="46024">trichostatin A</z:chebi> (TSA) and <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> (NaBt) significantly increased Wnt5a <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in SW620 </plain></SENT>
<SENT sid="7" pm="."><plain>Importantly, lower transcription of Wnt5a in SW620 than SW480 corresponded to multiple <z:chebi fb="0" ids="15358">histone</z:chebi> modifications, including lower levels of acetylated <z:chebi fb="0" ids="15358">histone</z:chebi> H3, H4 and H3K4me2 and higher levels of H3K27me3 in the promoter region </plain></SENT>
<SENT sid="8" pm="."><plain>The increase of H3Ac, H4Ac and H3K4me2 after NaBt treatment in SW620 confirmed the involvement of <z:chebi fb="0" ids="15358">histone</z:chebi> modifications in the transcriptional regulation of Wnt5a </plain></SENT>
<SENT sid="9" pm="."><plain>Additionally, NaBt treatment increased Î²-catenin signaling and diminished the difference in cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> ability between non-metastatic SW480 and metastatic SW620, suggesting that the HDAC inhibitor plays critical roles in the WNT signaling pathway and cell <z:mp ids='MP_0001532'>physiology</z:mp> that relate to <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, our study suggests the importance of Wnt5a in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and also indicates that Wnt5a silencing in the highly invasive human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell line might result from transcriptional regulation of the gene by <z:chebi fb="0" ids="15358">histone</z:chebi> modifications </plain></SENT>
</text></document>